<code id='B94CFAAB5A'></code><style id='B94CFAAB5A'></style>
    • <acronym id='B94CFAAB5A'></acronym>
      <center id='B94CFAAB5A'><center id='B94CFAAB5A'><tfoot id='B94CFAAB5A'></tfoot></center><abbr id='B94CFAAB5A'><dir id='B94CFAAB5A'><tfoot id='B94CFAAB5A'></tfoot><noframes id='B94CFAAB5A'>

    • <optgroup id='B94CFAAB5A'><strike id='B94CFAAB5A'><sup id='B94CFAAB5A'></sup></strike><code id='B94CFAAB5A'></code></optgroup>
        1. <b id='B94CFAAB5A'><label id='B94CFAAB5A'><select id='B94CFAAB5A'><dt id='B94CFAAB5A'><span id='B94CFAAB5A'></span></dt></select></label></b><u id='B94CFAAB5A'></u>
          <i id='B94CFAAB5A'><strike id='B94CFAAB5A'><tt id='B94CFAAB5A'><pre id='B94CFAAB5A'></pre></tt></strike></i>

          Home / hotspot / explore

          explore


          explore

          author:hotspot    Page View:3985
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In